The DDA will take part in a National Audit Office investigation into the costs of generic drugs to the NHS.
The study, which is expected to publish in the summer, aims to identify the extent of the increased spend on generic drugs, the causes of generic price increases and the Department of Health and Social Care’s response to the increased expenditure.
Recently, the prices of generics have increased creating unexpected pressure on the NHS, including on the concession/adjusted reimbursement price system. This was queried recently in the House of Commons.
In its response to the NAO, the DDA will highlight reimbursement system anomalies that result in loss-making dispensing. Practices may submit individual contributions via email to the NAO.